BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31905926)

  • 21. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
    Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway.
    Fang Y; Chai Z; Wang D; Kuang T; Wu W; Lou W
    Mol Cell Biochem; 2015 Jan; 399(1-2):269-78. PubMed ID: 25348361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
    Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
    Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3.
    Cao HY; Xiao CH; Lu HJ; Yu HZ; Hong H; Guo CY; Yuan JF
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6478-6485. PubMed ID: 31378887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis.
    Guo Q; Jing FJ; Xu W; Li X; Li X; Sun JL; Xing XM; Zhou CK; Jing FB
    Aging (Albany NY); 2019 Dec; 12(1):80-105. PubMed ID: 31895687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells.
    Zhou L; Wu Y; Guo Y; Li Y; Li N; Yang Y; Qin X
    Cancer Invest; 2017 May; 35(5):289-300. PubMed ID: 28368679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer.
    Ikeguchi M; Kaibara N
    Int J Mol Med; 2001 Dec; 8(6):661-6. PubMed ID: 11712083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
    Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
    Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
    Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
    Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin.
    Mao Z; Bian G; Sheng W; He S; Yang J; Dong X
    Oncol Rep; 2013 Nov; 30(5):2288-96. PubMed ID: 23982423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
    Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
    Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
    Wang LJ; Wang SG; Deng TX
    Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omega-3 Polyunsaturated Fatty Acids Enhance Cisplatin Efficacy in Gastric Cancer Cells by Inducing Apoptosis via ADORA1.
    Sheng H; Chen X; Liu B; Li P; Cao W
    Anticancer Agents Med Chem; 2016; 16(9):1085-92. PubMed ID: 27025656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects and mechanism of α-mangostin on chemosensitivity of gastric cancer cells.
    Li RR; Zeng DY
    Kaohsiung J Med Sci; 2021 Aug; 37(8):709-717. PubMed ID: 34003591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HMGB1 was negatively regulated by HSF1 and mediated the TLR4/MyD88/NF-κB signal pathway in asthma.
    Shang L; Wang L; Shi X; Wang N; Zhao L; Wang J; Liu C
    Life Sci; 2020 Jan; 241():117120. PubMed ID: 31825792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.